Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Biogen’s Coronavirus Woes Grow, Japan Unit Says Its Staffers Attended Boston Confab Too
March 10, 2020
- Shionogi Confirms Novel Coronavirus Infection at Its Group Company
March 10, 2020
- Aducanumab “on Track” for FDA Filing: Eisai CEO
March 9, 2020
- FTC Hits Torii with Cease, Desist, and Surcharge Payment Order over Price-Fixing for Calvan
March 9, 2020
- Japan’s Big 3 Generic Makers See 12.2% Price Cut vs. FY2018: Jiho Poll
March 9, 2020
- FDA Accepts Vibegron for Review; Target Date Set for Dec. 26
March 9, 2020
- Shionogi Boosts Stake in Tetra under Alzheimer's Deal; Buyout on the Cards
March 9, 2020
- Japan Ethical Drug Sales Down 1.2% in January: Crecon
March 9, 2020
- Large-Scale Clinical Data Confirms Efficacy and Safety of Switch to Vemlidy for Hep B: Gilead
March 9, 2020
- AnGes, Osaka Univ. to Pair Up to Develop DNA Vaccines for COVID-19
March 6, 2020
- Chugai, Teijin Suffer Hefty 9% Cuts in 2020 Drug Price Revision: Jiho Poll
March 6, 2020
- Keytruda Remains Top-Seller in February Drug Ranking: Encise
March 6, 2020
- Takeda Joins Fight against COVID-19, Eyes Plasma Product Launch in 9-18 Months
March 5, 2020
- Braftovi/Mektovi Filed for Colorectal Cancer in Japan: Ono
March 5, 2020
- Takeda Closes Non-Core Asset Divestment to Stada
March 5, 2020
- 1st Patient Dosed Telomelysin Together with Radiotherapy in Japan PII Study for Esophageal Cancer: Chugai
March 5, 2020
- Asahi Kasei Completes Acquisition of Veloxis
March 5, 2020
- Sumitomo Dainippon Creates Chief Scientific Officer Post to Optimize Portfolio
March 4, 2020
- Shionogi’s Fetcroja Bags EU Panel Nod
March 4, 2020
- Sawai Refrains from Sales Reps' Doctor Visits Through March 13
March 4, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…